AV7909 (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant) is being studied for use as a third-generation anthrax vaccine.
This candidate consists of BioThrax® (Anthrax Vaccine Adsorbed) in combination with a novel immunostimulatory compound, CPG 7909.
ACTIVE CLINICAL TRIALS NCT03877926: A Phase 3, multicenter, randomized, double-blind, parallel-group trial designed to evaluate the lot consistency (using three consecutively manufactured lots), immunogenicity, and safety of AV7909 administered in healthy adults for an indication of postexposure prophylaxis (PEP) of anthrax
COMPLETED CLINICAL TRIALS:
- A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels
- Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults